Advances in the approach to novel drug clinical development for breast cancer.

about

KSP inhibitor SB743921 inhibits growth and induces apoptosis of breast cancer cells by regulating p53, Bcl-2, and DTL Adverse event-related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries.Prodigiosenes conjugated to tamoxifen and estradiol.

P2860

Q28831422-DBB8D9AD-E7F9-4D16-8026-31722036B083 Q38840175-6AC74B21-3886-4A60-B307-53FA3802AF5A Q48752979-BEFBC59E-EF68-45E7-834D-61C82AE6A954

P2860

Advances in the approach to novel drug clinical development for breast cancer.

Item

http://www.wikidata.org/entity/Q38206546

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Advances in the approach to novel drug clinical development for breast cancer.

@en

type

Item

label

Advances in the approach to novel drug clinical development for breast cancer.

@en

prefLabel

Advances in the approach to novel drug clinical development for breast cancer.

@en

P1476

Advances in the approach to novel drug clinical development for breast cancer.

@en

P2093

Cristiano Ferrario

http://www.w3.org/2001/XMLSchema#string

Gerald Batist

http://www.w3.org/2001/XMLSchema#string

P2860

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Combination anastrozole and fulvestrant in metastatic breast cancer

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

Comprehensive molecular portraits of human breast tumours

Genome sequencing identifies a basis for everolimus sensitivity

Continuous cultures of fused cells secreting antibody of predefined specificity

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

P304

647-668

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17460441.2014.911282

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24758225

http://www.w3.org/2001/XMLSchema#string

Advances in the approach to novel drug clinical development for breast cancer.

about

P2860

P2860

Advances in the approach to novel drug clinical development for breast cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698